Zimmer Biomet Holdings, Inc. (ZIM.F)
- Previous Close
105.60 - Open
105.10 - Bid 105.35 x 30000
- Ask 105.80 x 30000
- Day's Range
105.10 - 105.10 - 52 Week Range
97.14 - 134.15 - Volume
1 - Avg. Volume
1 - Market Cap (intraday)
21.872B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
24.67 - EPS (TTM)
4.26 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield 0.89 (0.85%)
- Ex-Dividend Date Jun 26, 2024
- 1y Target Est
188.04
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
www.zimmerbiomet.comRecent News: ZIM.F
Performance Overview: ZIM.F
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIM.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIM.F
Valuation Measures
Market Cap
21.87B
Enterprise Value
27.01B
Trailing P/E
24.69
Forward P/E
14.10
PEG Ratio (5yr expected)
1.71
Price/Sales (ttm)
3.19
Price/Book (mrq)
1.86
Enterprise Value/Revenue
3.93
Enterprise Value/EBITDA
13.56
Financial Highlights
Profitability and Income Statement
Profit Margin
12.93%
Return on Assets (ttm)
4.43%
Return on Equity (ttm)
7.80%
Revenue (ttm)
7.45B
Net Income Avi to Common (ttm)
963.9M
Diluted EPS (ttm)
4.26
Balance Sheet and Cash Flow
Total Cash (mrq)
393M
Total Debt/Equity (mrq)
47.68%
Levered Free Cash Flow (ttm)
1.07B